Advertising disclosure — We may earn a commission if you start care through some of these links, at no extra cost to you. How we're funded. Order reflects our editorial rubric and our commercial relationships; scores are ours alone.
Luna Fit
HealthSource review
One of the few programs that documents its all-50-state footprint rather than asserting it, with an oral tirzepatide route and a starter-dose plan priced the same as the full dose.
- Semaglutide
- $199 every 4 weeks (13 charges a year; $174.50 per 4 weeks on the 8-week plan)
- Tirzepatide
- $299 every 4 weeks (13 charges a year; $274.50 per 4 weeks on the 8-week plan)
- Coverage
- All 50 states
- Brand-name
- Compounded only
The Luna Fit scorecard
HealthSource scored on our six women's-health factors. See the methodology.
What we like
- The only provider in this batch whose all-50-state claim is documented on its own service-areas page rather than asserted in marketing copy
- An oral tirzepatide program alongside the injections
- Starter-dose and full-dose plans cost the same, so titrating up does not raise the bill
- An 8-week plan brings semaglutide to $174.50 per four weeks, which the price ladder does not advertise
- Medication, supplies and 24/7 care-team messaging are all inside the plan price with no membership fee
- Clinical care runs through MD Integrations, named rather than described vaguely
- Automatic refund if a monthly reassessment is not filled
The caveats
- Billed every four weeks, not monthly — thirteen charges a year, so the effective annual cost is about 8% above the sticker
- Never actually claims flat pricing across all doses; the variants it sells happen to cost the same
- The form of the oral tirzepatide — sublingual, troche or swallowed tablet — is not disclosed anywhere
- No lab or monitoring program at all; oversight is a monthly reassessment and messaging
- The compounding pharmacy is not named, and individual practitioners are not listed
- Charges already processed are non-refundable, and dispensed prescriptions cannot be refunded
- No menopause, PCOS, hormone or contraception content on any GLP-1 page
The bottom line
Best for: Women who want an oral tirzepatide option and a documented nationwide footprint, and who will read the four-week billing cycle rather than assuming it is monthly. One of the few programs that documents its all-50-state footprint rather than asserting it, with an oral tirzepatide route and a starter-dose plan priced the same as the full dose.
Ranked #67 of 80 providers we reviewed for women — see our #1 pick, CoreAge Rx, for comparison. PCOS & hormonal suitability is where HealthSource scores lowest, at 60/100. If that is your sticking point, start with the full field we rank against HealthSource.
Others in HealthSource's score range
The providers scoring closest to HealthSource on the same six factors. One of those comparisons is written out in full: how HealthSource and CoreAge Rx compare on the Luna Fit Score, 19 points apart on the Luna Fit Score. Directly below HealthSource sits WellMedr at #68 with 67/100 — see the WellMedr alternatives, scored on the same six factors if that is the band you are shopping in.
See all 80 providers we've reviewed for women — ranked on the same rubric, with scores and pricing side by side.
Pricing, states and verification reflect HealthSource's public disclosures at last review; the Luna Fit Score is our editorial judgment per the methodology. Prices change — confirm on HealthSource's site. Not medical advice; see our disclosure.